Product Code: ETC9958579 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
Publisher: 6Wresearch | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 | |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United States (US) Acute Myeloid Leukemia Market Overview |
3.1 United States (US) Country Macro Economic Indicators |
3.2 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, 2021 & 2031F |
3.3 United States (US) Acute Myeloid Leukemia Market - Industry Life Cycle |
3.4 United States (US) Acute Myeloid Leukemia Market - Porter's Five Forces |
3.5 United States (US) Acute Myeloid Leukemia Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 United States (US) Acute Myeloid Leukemia Market Revenues & Volume Share, By Treatment Type, 2021 & 2031F |
3.7 United States (US) Acute Myeloid Leukemia Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.8 United States (US) Acute Myeloid Leukemia Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
3.9 United States (US) Acute Myeloid Leukemia Market Revenues & Volume Share, By Distribution Channel, 2021 & 2031F |
4 United States (US) Acute Myeloid Leukemia Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Technological advancements in treatment options for acute myeloid leukemia |
4.2.2 Increasing prevalence of acute myeloid leukemia in the US |
4.2.3 Growing healthcare expenditure and funding for cancer research |
4.3 Market Restraints |
4.3.1 High cost of treatment and therapy for acute myeloid leukemia |
4.3.2 Stringent regulatory requirements for drug approvals in the US |
5 United States (US) Acute Myeloid Leukemia Market Trends |
6 United States (US) Acute Myeloid Leukemia Market, By Types |
6.1 United States (US) Acute Myeloid Leukemia Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Myeloblastic, 2021- 2031F |
6.1.4 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Promyelocytic, 2021- 2031F |
6.1.5 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Myelomonocytic, 2021- 2031F |
6.2 United States (US) Acute Myeloid Leukemia Market, By Treatment Type |
6.2.1 Overview and Analysis |
6.2.2 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Chemotherapy, 2021- 2031F |
6.2.3 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Targeted Therapy, 2021- 2031F |
6.2.4 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Immunotherapy, 2021- 2031F |
6.2.5 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Hormone Therapy, 2021- 2031F |
6.2.6 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Others, 2021- 2031F |
6.3 United States (US) Acute Myeloid Leukemia Market, By Route of Administration |
6.3.1 Overview and Analysis |
6.3.2 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Oral, 2021- 2031F |
6.3.3 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Parenteral, 2021- 2031F |
6.3.4 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United States (US) Acute Myeloid Leukemia Market, By End-Users |
6.4.1 Overview and Analysis |
6.4.2 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.3 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Homecare, 2021- 2031F |
6.4.4 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Speciality Centres, 2021- 2031F |
6.4.5 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Others, 2021- 2031F |
6.5 United States (US) Acute Myeloid Leukemia Market, By Distribution Channel |
6.5.1 Overview and Analysis |
6.5.2 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Hospital Pharmacy, 2021- 2031F |
6.5.3 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Online Pharmacy, 2021- 2031F |
6.5.4 United States (US) Acute Myeloid Leukemia Market Revenues & Volume, By Retail Pharmacy, 2021- 2031F |
7 United States (US) Acute Myeloid Leukemia Market Import-Export Trade Statistics |
7.1 United States (US) Acute Myeloid Leukemia Market Export to Major Countries |
7.2 United States (US) Acute Myeloid Leukemia Market Imports from Major Countries |
8 United States (US) Acute Myeloid Leukemia Market Key Performance Indicators |
8.1 Patient survival rates post-treatment |
8.2 Adoption rate of novel therapies for acute myeloid leukemia |
8.3 Number of clinical trials for new treatments conducted in the US |
9 United States (US) Acute Myeloid Leukemia Market - Opportunity Assessment |
9.1 United States (US) Acute Myeloid Leukemia Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 United States (US) Acute Myeloid Leukemia Market Opportunity Assessment, By Treatment Type, 2021 & 2031F |
9.3 United States (US) Acute Myeloid Leukemia Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.4 United States (US) Acute Myeloid Leukemia Market Opportunity Assessment, By End-Users, 2021 & 2031F |
9.5 United States (US) Acute Myeloid Leukemia Market Opportunity Assessment, By Distribution Channel, 2021 & 2031F |
10 United States (US) Acute Myeloid Leukemia Market - Competitive Landscape |
10.1 United States (US) Acute Myeloid Leukemia Market Revenue Share, By Companies, 2024 |
10.2 United States (US) Acute Myeloid Leukemia Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |